Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-06-04T02:07:22.620Z Has data issue: false hasContentIssue false
  • English
  • Français

Lack of effect of naloxone and schizophrenic auditory hallucinations

Published online by Cambridge University Press:  09 July 2009

C. P. L. Freeman  and
C. G. Fairburn
C. P. L. Freeman*
Affiliation:
University Department of Psychiatry, Edinburgh
C. G. Fairburn
Affiliation:
University Department of Psychiatry, Edinburgh
*
1Address for correspondence: Dr C. P. L. Freeman, University Department of Psychiatry, Royal Edinburgh Hospital, Morningside Park, Edinburgh EH10 5HF.
Get access Rights & Permissions [Opens in a new window]

Synopsis

Opiate-like neuropeptides, such as beta endorphin, have been implicated in the aetiology of schizophrenic symptoms; and the relief of some symptoms, particularly auditory hallucinations, has been reported after injection of naloxone. An opiate antagonist, naloxone 1·6 mg, and placebo were administered in a double-blind, crossover design to 13 constantly hallucinating schizophrenic patients. Naloxone was found to be no different from placebo in its effect.

Type
Brief Communication
Information
Psychological Medicine , Volume 11 , Issue 2 , May 1981 , pp. 405 - 407
Copyright
Copyright © Cambridge University Press 1981

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baldessarini, R. J. (1978). Chemotherapy in Psychiatry. Boston University Press: Cambridge, Mass.Google Scholar
Bloom, F., Segal, D. & Ling, N. (1976). Endorphins: profound behavioural effects in rats suggest new aetiological factors in mental illness. Science 194, 630–632.CrossRefGoogle ScholarPubMed
Cox, B., Ary, M. & Lomax, P. (1976). Changes in sensitivity to apomorphine during morphine dependence and withdrawal in rats. Journal of Pharmacology and Experimental Therapeutics 196, 637–641.Google ScholarPubMed
Feighner, J. P., Robins, E., Guze, S. B., Woodruff, R. A., Winokur, G. & Munoz, R. (1972). Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry 26, 57–63.CrossRefGoogle ScholarPubMed
Gunne, L. M., Lindström, L. & Terenius, L. (1977). Naloxone-induced reversal schizophrenic hallucinations. Journal of Neural Transmission 40, 13–19.CrossRefGoogle ScholarPubMed
Janowsky, D. S., Segal, D. S., Abrams, A., Bloom, F. & Guillemin, R. (1977). Negative naloxone effects in schizophrenic patients. Psychopharmacology 53, 295–297.CrossRefGoogle ScholarPubMed
Jones, R. (1978). Naloxone induced mood and physiologic changes in normal volunteers. In Endorphins in Mental illness (ed. Usdin, E. and Bunney, W. E.), pp. 484–491. Macmillan: London.Google Scholar
Lipinski, J., Meyer, R., Kornetsky, C. & Cohen, B. M. (1979). Naloxone in schizophrenia. Lancet i, 1292.CrossRefGoogle Scholar
Mackay, A. V. P. (1979). Psychiatric implications of endorphin research. British Journal of Psychiatry 135, 470–473.CrossRefGoogle ScholarPubMed
Overall, J. E. & Gorham, D. R. (1962). The Brief Psychiatric Rating Scale. Psychological Reports 10, 799–812.CrossRefGoogle Scholar
Terenius, I., Wahlstrom, A., Lindström, L. & Widerlov, E. (1976). Increased CSF levels of endorphins in chronic psychosis. Neuroscience Letters 3, 157–162.CrossRefGoogle ScholarPubMed
Verebey, K., Volavka, J. & Clovet, D. (1978). Endorphins in psychiatry. An overview and a hypothesis. Archives of General Psychiatry 35, 877–888.CrossRefGoogle ScholarPubMed